Metabolon and the University of Michigan Announce Agreement
News Oct 24, 2008
The agreement puts in place a number of activities to help progress Metabolon's Prostarix(TM) line of prostate cancer diagnostics including an exclusive license for Metabolon to use prostate cancer aggressitivity markers that were discovered in a collaborative research project between the University of Michigan and Metabolon. This intellectual property will provide the company with a significant competitive advantage in the field of prostate cancer diagnosis and will serve as the basis for Prostarix--which is expected to be launched in late 2009. The agreement also includes a sponsored research agreement with Dr. ArunSreekumar, assistant professor of pathology at the University of Michigan, aimed at a deeper understanding into the role the biomarkers play in the onset of aggressiveness.
"As the second major cause of cancer-related death in the US, prostate cancer creates unique challenges to accurately predict the likelihood of metastasis. Metabolon continues to work with leading researchers like those at the University of Michigan to develop easy-to-use diagnostic tools to better understand aggressiveness and metastatic potential of prostate cancer and to help doctors and patients make critical treatment decisions," explained John Ryals, chief executive at Metabolon.
According to the American Cancer Society, prostate cancer is the most common non-skin cancer found in men in the United States, with one in six men expected to develop the disease during his lifetime. Over 185,000 men are newly diagnosed with prostate cancer each year. Development and progression of the disease are monitored using a prostate specific antigen (PSA) test. Once patients are diagnosed, there are several options: active surveillance, androgen deprivation or radiation therapy, or prostatectomy. These options are based on the likelihood the tumor will become metastatic and spread. However, predicting the likelihood of metastasis has traditionally been very difficult.
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE
Lab Innovations returns to the NEC, Bimingham , UKNews
Save the date for the UK’s only lab-dedicated exhibition showcase!READ MORE
Comments | 0 ADD COMMENT
International Conference on Biobetters and Regulatory Affairs
Jun 27 - Jun 28, 2018